Levemir and Lantus used to be the two competitors on the market for basal insulin treatments. However, since then, some new players have entered this industry, such as Tresiba. Patients above the age of 18 with type 1 or type 2 diabetes are treated with basal insulin. What makes this new member of the basal gang different from the others available?
What is Tresiba?
Tresiba is an insulin pen that uses FlexTouch technology and is administered once daily. As Tresiba lasts up to 42 hours, it provides you with more flexibility when it comes to meal planning than Lantus does.
In contrast to Lantus, persons with Type 2 diabetes were able to change the timing of their daily dose and still maintain blood sugar control during a clinical investigation.
Study Choice for Patients with Type 2 Diabetes
This study found that there were no adverse effects on blood sugar control when patients with type 2 diabetes changed their Tresiba dosage schedule by 8 to 40 hours. The same kind of control that was obtained by taking Lantus at the same time every day was still available while taking Tresiba at different times.
NOTE: It’s crucial to always make sure there are at least eight hours between doses while taking Tresiba at different times.
Study Choice for Patients with Type 1 Diabetes
When patients with Type 1 diabetes were given a once-daily injection of Tresiba together with fast-acting insulin during mealtimes, the study found that both Tresiba and Lantus produced comparable blood sugar control outcomes.
Notifications and Safety Data Regarding Tresiba
Don’t Share: Tresiba is a drug that should never be shared between patients, not even when the needle is changed, due to its FlexTouch pen shape. Patients who share pen-format drugs run the danger of potentially spreading blood infections.
Hypoglycemic Control: When using Tresiba, blood sugar levels should always be checked. Because using insulin might alter how well your blood sugar is regulated, it’s critical to continuously check your levels to avoid hypo- and hyperglycemic episodes.
If hypoglycemia strikes, it should be handled properly since it has the potential to be fatal. Ensure that you are seeing your doctor rather than adjusting the dosage of Tresiba on your own.
Allergic Reaction: Using insulin products can cause severe, occasionally fatal anaphylaxis. When using this medicine, be sure to notify your doctor right away if you observe any allergic reactions.
Fluid Retention: Using thiazolidinedione (TZD) can occasionally result in both heart failure and fluid retention. Be careful to keep an eye out for any possible heart failure symptoms, such as:
- lightheadedness
- Weary
- Diminished Hunger
- Chest Pain
- Quick Breathing
- Breathlessness
- Phlegmy or dry cough
- Retention of water
- bloating
- Palpitations in the Heart
- swollen feet or legs
- Gain of Weight
Tresiba Usage in Pediatric Patients with Type 1 or Type 2 Diabetes
Children with Type 1 or Type 2 diabetes who are one year of age or older may use Tresiba. Nevertheless, juvenile patients are unable to utilize Tresiba if they have not yet used five units of Tresiba for their daily dose of basal insulin.
Make careful to ask your child’s physician about Tresiba usage and find out what their advise is. However, in order to lower the risk of hypoglycemia episodes, pediatric patients who begin taking Tresiba usually do so at 80% of their current basal use. Doctors advise starting a child with Type 1 diabetes at ⅓ to ½ of their total daily dose (TDD) of basal insulin.
The Tresiba offers a lower push button extension than other basal insulin pen types. For younger pediatric patients who are capable of administering injections on their own, this makes injecting much simpler.
Read Also: Five Alternatives to Chicken Broth
In summary
It’s crucial to see your doctor before thinking about switching to Tresiba to receive their advice on whether this basal treatment option would be helpful for you.
In general, Tresiba appears to be an excellent option for people who want more insulin regimen flexibility. If you’ve already switched, please share your thoughts about this insulin in the comments section below.
DiabetesCouncils Article | Reviewed by Dr. Christine Traxler MD on May 20, 2020
Be the first to comment on "Reviews of Tresiba"